TG Therapeutics announces updated data on five-year data from ULTIMATE trials

TG Therapeutics announced updated data presentations including new five-year data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI in patients with relapsing forms of multiple sclerosis, at the 2024 European Committee for Treatment and Research in Multiple Sclerosis, ECTRIMS, annual meeting. DATA HIGHLIGHTS: Poster Presentation: Five years of BRIUMVI in relapsing multiple sclerosis: Results from the open-label extension of ULTIMATE I and II studies. Patients who continued BRIUMVI treatment exhibited low and decreasing annualized relapse rate throughout the observation period. During Year 1 of the open label extension, patients who switched from teriflunomide to BRIUMVI experienced a significant reduction in ARR. After 5 years of continuous BRIUMVI treatment, 8% of patients had Confirmed Disability Progression lasting 24 weeks compared to 14.3% of patients who switched from teriflunomide to BRIUMVI, and 92% remained progression free with continuous BRIUMVI treatment. 17% of patients treated with BRIUMVI continuously for 5 years achieved Confirmed Disability Improvement lasting at least 24 weeks compared to 12.2% of patients who switched from teriflunomide to BRIUMVI, resulting in one in six patients experiencing improvement in disability after 5 years of continuous BRIUMVI treatment. The overall safety profile of BRIUMVI remained consistent over 5 years of continuous treatment in an exposure-adjusted analysis of adverse events.